Why AI matters at this scale

Glaukos Corporation is a medical technology company focused on transforming the treatment of glaucoma, a leading cause of blindness. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its iStent inject® device and has built a portfolio of implants and pharmaceuticals. As a growing mid-market player with over 500 employees, Glaukos operates at a critical scale: large enough to generate significant clinical and operational data, yet agile enough to implement focused technological innovations without the inertia of a massive enterprise. In the highly regulated and competitive ophthalmic device sector, AI is not merely an efficiency tool but a potential source of clinical differentiation, enabling smarter devices, superior patient outcomes, and more efficient commercial and R&D operations.

Concrete AI Opportunities with ROI Framing

1. Enhanced Surgical Planning & Simulation: By applying AI and computational fluid dynamics to pre-operative optical coherence tomography (OCT) scans, Glaukos could develop a surgical planning assistant. This tool would model aqueous humor outflow for individual patient anatomies to predict the optimal placement and combination of MIGS devices. The ROI is direct: improving first-surgery success rates enhances clinical adoption, reduces revision surgeries, and strengthens the value proposition versus competitors, directly impacting market share.

2. Intelligent Post-Market Surveillance: Manual review of adverse event reports is slow and reactive. An NLP system that continuously monitors electronic health records (with appropriate privacy safeguards), patient-reported outcomes, and global regulatory databases can identify subtle patterns or early signals of device-related issues. For a company of Glaukos's size, this mitigates massive regulatory and financial risk by enabling proactive responses, potentially avoiding costly recalls or litigation.

3. Optimized Commercial Operations: Machine learning applied to integrated data from CRM (like Salesforce), hospital purchasing systems, and procedure volumes can generate hyper-accurate sales forecasts and inventory needs. For a mid-market firm, this means working capital is not tied up in excess inventory, and commercial teams can focus on high-potential accounts, improving sales efficiency and profitability.

Deployment Risks for the 501-1000 Size Band

Implementing AI at this scale presents distinct challenges. First, resource allocation is a constant tension; dedicating top engineering and clinical talent to speculative AI projects can strain core product development. A clear, phased pilot strategy is essential. Second, data infrastructure may be fragmented across legacy systems, requiring upfront investment in data unification before model training can begin. Third, the regulatory pathway for AI/ML in healthcare is evolving. Any AI tool touching clinical decision-making may require FDA clearance, a process demanding significant time and financial investment that must be factored into the product roadmap. Finally, change management is critical; surgeons are the end-users, and any AI tool must be designed to augment, not replace, their expertise, requiring extensive clinical collaboration and training to ensure adoption.